Caladrius Biosciences (NASDAQ: CLBS) and Tivity Health (NASDAQ:TVTY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Earnings and Valuation
This table compares Caladrius Biosciences and Tivity Health’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Caladrius Biosciences||$35.28 million||1.25||$22.97 million||($1.78)||-2.60|
|Tivity Health||$556.94 million||2.87||$63.71 million||$1.68||23.84|
Insider and Institutional Ownership
5.7% of Caladrius Biosciences shares are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by insiders. Comparatively, 8.4% of Tivity Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Caladrius Biosciences has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Caladrius Biosciences and Tivity Health, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Caladrius Biosciences presently has a consensus price target of $9.50, indicating a potential upside of 105.18%. Tivity Health has a consensus price target of $47.14, indicating a potential upside of 17.71%. Given Caladrius Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Caladrius Biosciences is more favorable than Tivity Health.
This table compares Caladrius Biosciences and Tivity Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Tivity Health beats Caladrius Biosciences on 9 of the 14 factors compared between the two stocks.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
About Tivity Health
Tivity Health, Inc. provides fitness and health improvement programs in the United States. The company offers SilverSneakers senior fitness program to the members of Medicare advantage, Medicare supplement, and group retiree plans; and Prime fitness, a fitness facility access program through commercial health plans and employers. It also provides health plans through WholeHealth Living program; and health services, such as chiropractic care, acupuncture, physical therapy, occupational therapy, speech therapy, and others. The company was formerly known as Healthways, Inc. and changed its name to Tivity Health, Inc. in January 2017. Tivity Health, Inc. was founded in 1981 and is headquartered in Franklin, Tennessee.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.